Key Takeaways
- CVC Catalyst acquired WillowWood, Blue Sea Capital, Arbogast family.
- Sector: Healthcare, Healthtech & Medtech.
- Geography: United States.
Analysis
CVC Catalyst, the mid-market investment arm of global private equity giant CVC, has secured a majority ownership in WillowWood, a prominent American manufacturer of prosthetic devices and components. This strategic acquisition marks a significant move for CVC into the specialized medical technology sector, aiming to accelerate growth for the century-old company.
The transaction sees CVC Catalyst acquiring its stake from Blue Sea Capital. Importantly, the founding Arbogast family and WillowWood's current management team are reinvesting substantially, signaling confidence in the company's future trajectory under new ownership. This continuity is expected to ensure a smooth transition and leverage existing expertise.
Founded in 1907, WillowWood has established itself as a pioneer in mobility solutions for individuals with limb loss. The company is renowned for its development of the critical gel liner, a key interface between a patient's residual limb and their prosthetic. Beyond this foundational product, WillowWood offers an extensive catalog of approximately 1,000 stock-keeping units (SKUs), alongside bespoke solutions for complex cases, and has expanded its portfolio to include advanced prosthetic feet, knees, and custom fabrication services.
Since Blue Sea Capital's initial investment in 2018, WillowWood has undergone a significant transformation. Under the leadership of co-chief executives Mahesh Mansukhani and Daniel Rubin, who will remain at the helm, the company has broadened its product offerings, enhanced its commercial operations, bolstered its research capabilities, and integrated in-house manufacturing facilities in Ohio and Arizona. This period has seen the launch of 18 new products since 2021, underscoring a robust innovation pipeline.
Cathrin Petty, managing partner and global head of healthcare at CVC, highlighted WillowWood's exceptional legacy and market leadership. She stated that CVC Catalyst intends to significantly increase investment in research and development, driving further product innovation. A key strategic priority will be expanding WillowWood's international footprint, particularly establishing a direct commercial presence in Europe, leveraging CVC Healthcare's global network and deep MedTech experience. Phil Robinson, a partner at CVC, views the European market as a substantial opportunity well-aligned with CVC's investment strategy for high-potential, inflection-point companies.
This acquisition aligns with CVC's established playbook in the healthcare sector, demonstrated by previous successful investments in companies like Rayner, Spectrum, and Therakos. The firm's approach typically involves accelerating research, strengthening commercial capabilities, pursuing international expansion, and executing strategic bolt-on acquisitions. The deal is anticipated to close in the third quarter of 2026, pending regulatory approvals. Financial details of the transaction have not been disclosed.